TEAM
TEAM
Extensive Private and Public Healthcare Investment Expertise
TEAM
TEAM
Extensive Private and Public Healthcare Investment Expertise
1
 
Board & Management
Investment Team
Business Development, Risk and Compliance
Operations
  • Didier de Montmollin

    Didier de Montmollin

    A founding partner of DGE Attorneys at law and recognized as an expert on Swiss banking law. Member of the Executive Committee of the Swiss Bar Association’s Anti-Money Laundering Regulatory Authority. One of four counsel appointed by the Swiss Bankers Association for investigations of violations by member banks of the agreement on the Swiss bank’s Code of Conduct regarding the exercise of due diligence.


    Board Member
    Read more
  • Ulrich Geilinger

    Ulrich Geilinger

    Over 25 years experience in the Venture Capital Industry. PhD ETH Zurich in Natural Sciences and Industrial Engineering. Previously in management functions at Innoventure, Credit Suisse, Apax and Vontobel.

    Board Member
    Dr
    Read more
  • Andreas Wicki

    Andreas Wicki

    Successful healthcare entrepreneur and investor with over 25 years of experience in the pharmaceutical and biotechnology industries. MSc and PhD in chemistry and biochemistry from the University of Berne, Switzerland. Previously co-owner and CEO of ANAWA Holding AG and Clinserve AG, two Contract Research Organisations specialising in analytical services. Board member of Harmony Biosciences, Buchler, and Pacira Pharmaceuticals.

    Management, CEO
    Dr
    Read more
  • Erwin Troxler

    Erwin Troxler

    Over 20 years of experience in investment management, audit and finance. Holds a degree of the Lucerne School of Economics and Business Administration and is a Swiss Certified Accountant. Previously account manager at PricewaterhouseCoopers and Julius Baer responsible for clients in the financial services sector. Chairman of Swiss Association of Investment Companies (SAIC).

    Management, CFO
    Read more
  • Matthias Fehr

    Matthias Fehr

    Over twenty years of experience in private and public equity investment management and research. Former senior sell-side analyst at Lombard Odier for biotech and medical technology industries; former scientist at the Swiss Federal Institute of Technology. MSc and PhD in chemistry from ETH Zurich and Chartered Financial Analyst since 2002. Board member of Swixx Biopharma, Sphingotec, Numab, Farmalatam and Board Observer Tata 1mg.

    Management, Head Private Equity
    Dr
    Read more
  • Ivo Staijen

    Ivo Staijen

    Over 15 years experience in the pharma industry and in investment analysis and portfolio management. PhD in biotechnology from ETH Zurich and MSc in chemistry from the University of Groningen. Previously senior biotechnology analyst at Bank Sarasin and department head at MDS Pharma Services.

    Management, Head Public Equity, Portfolio Manager
    Dr
    Read more
  • Alexander Asam

    Alexander Asam

    More than 25 years of experience in the life sciences and private equity businesses. Former managing director and partner of Deutsche Venture Capital (DVC) / Deutsche Bank. Various positions at Hoechst AG, Aventis S.A. (now: Sanofi) and LION Bioscience AG, among others member of the IPO Core Team (dual listing Germany and USA). MBA degree from ASTON Business School, Birmingham and a MSc and PhD in chemistry from University of Heidelberg. Currently board member of Mineralys Therapeutics and Aculys Pharma. Board observer at Swixx Biopharma.

    Investment Advisor Private Equity
    Dr
    Read more
  • Priyanka Belawat

    Priyanka Belawat

    Over thirteen years of experience in venture and private equity investing in the healthcare space. Actively manages investments in bio-pharma, especially drug development in oncology, neurology, sepsis, fibrosis etc. in geographies like the US, Europe and selected emerging markets like China and India. Dr. Belawat holds a doctorate in molecular biology and genetics from the University of Zurich and a post-doc at HKUST. Board member of Neurelis Inc. (USA), Adrenomed AG (Germany), BioAtla (USA), IO Biotech (Denmark) and board observer to Sai Lifesciences (India). 

    Investment Advisor Private Equity
    Dr
    Read more
  • Emil Bujak

    Emil Bujak

    Over ten years of experience in venture capital and medicinal research. Prior experience as a registered pharmacist, and in antibody technology research at Philogen. Holds a PhD and an MSc in Medicinal and Industrial Pharmaceutical Sciences from ETH Zurich and is a Chartered Financial Analyst (CFA) since 2019. Board member of Polyneuron, board observer at Pyxis Oncology.

    Advisor to HBM Partners
    Dr
    Read more
  • Michael Buschle

    Michael Buschle

    More than 25 years experience in biotech and pharma. PhD from the University of London. Research at St. Jude’s Childrens Research Hospital, Boehringer Ingelheim-owned Institute of Molecular Pathology, Vienna. Industrial experience: Boehringer Ingelheim, Co-founder of Intercell with successful IPO, Chief Scientific Officer of Glenmark Pharmaceuticals.

    Advisor to HBM Partners
    Dr
    Read more
  • Steve Chen

    Steve Chen

    Over 15 years of professional public market investing experience with focus on China and global healthcare industry. MBA from Wharton Business School, MSc in Biochemistry and Molecular Biology from Georgetown University and BSc from Nankai University, and a CFA charterholder. Previously managed proprietary trading portfolio for Barclays Capital New York and Huatai Securities’ Hong Kong subsidiary, and was Portfolio Manager for a large closed-end exchange listed mutual fund in China.

    Managing Director and Investment Advisor HBM Partners Hong Kong Limited
    Read more
  • Miranda Guo

    Miranda Guo

    5 years experience in Chinese healthcare industry with experience in investment analysis, business development and post investment management. MSc in Biomedical Engineering from the Chinese University of HongKong. Previously PE investment manager at LEPU Medical Technology and investment analyst at BGI Genomics.

    Investment Advisor HBM Partners Hong Kong Limited
    Read more
  • Mirjam Heeb

    Mirjam Heeb

    Over 18 years experience in the pharma industry and in global healthcare investment analysis and portfolio management. MSc in Molecular Biology from the University of Basel and McGill University, Montreal. Most recently spent 4 years as senior portfolio manager of the GAM Health Innovation Fund with GAM Investment Management. Prior to this senior manager in global business development with Vifor Pharma (formerly Galenica Group). Former sell-side and buy-side analyst as well as portfolio manager for medical technology and biopharma industries with the Bellevue Group.

    Investment Advisor Public Equity
    Read more
  • Michael Jasulavic

    Michael Jasulavic

    Over 10 years of experience in healthcare investment research, strategy and trade execution. MS in Medical Science from MCP/Hahnemann University. Previously biotechnology analyst at Traxis Partners, Sivik Global Healthcare and Jefferies Asset Management.

    Advisor to HBM Partners
    Read more
  • Romain Kooger

    Romain Kooger

    Over 6 years life science research experience. PhD and postdoc in biophysics and microbiology at ETH Zurich, BSc and MSc in biochemistry from the university of Geneva with an emphasis on chemistry and neurosciences. Year-long research internships at Leiden University and Nanjing University, China.

    Investment Advisor Private Equity
    Dr
    Read more
  • Chandra P. Leo

    Chandra P. Leo

    Over twenty years of experience in private equity, clinical practice and biomedical research. Doctor of Medicine from Freie Universität Berlin (Charité), MAS in Medicines Development from University of Basel, MBA with distinction from INSEAD. Former postdoctoral scientist at Stanford University, physician at University Hospital Leipzig and principal at Wellington Partners. Board member of Dren Bio, Fore Biotherapeutics, Monte Rosa and River Renal, board observer at Karius.

    Investment Advisor Private Equity
    Dr
    Read more
  • Gavin MacGregor

    Gavin MacGregor

    Over 13 years’ experience in the pharma industry and in global healthcare investment analysis. 1st Class BSc in Biomedical Sciences from the University of Manchester and a Chartered Management Accountant (CIMA). Previously spent 3 years as Finance analyst with GlaxoSmithKline, 6 years as European Pharma equity analyst with Lehman Brothers and Credit Suisse, and 5 years as senior global healthcare analyst with Martin Currie Investment Management. 

    Investment Advisor Public Equity
    Read more
  • Asun Monfort

    Asun Monfort

    More than 14 years of experience in life science research and development of advanced therapies. PhD in pharmaceutical development of innovative medicines from University of Navarra. Postdoc at the Stem Cell Institute at the University of Cambridge and postdoc at the Institute for Molecular Health Sciences at ETH. Previously senior scientist at ETH Zurich, Switzerland.

    Investment Advisor Private Equity
    Dr
    Read more
  • Thomas Thaler

    Thomas Thaler

    Over 25 years experience in the investment management, financial research and in the biotechnology and medical technology industry. PhD in life sciences and MSc in biochemistry and a masters degree in business administration from ETH Zurich. Previously senior equity analyst at Bank Julius Baer and in senior management positions with Sulzer Medica, Schneider and Boston Scientific. Board member of Vascular Dynamics, Valcare Medical, Shape Memory Medical, Cardialen and MicroOptx.

    Investment Advisor Public & Private Equity
    Dr
    Read more
  • Cindy Chen

    Cindy Chen

    Over 15 years of professional experience in financial market with focus on investment in Chinese companies, fund management, operation and compliance. MSc in Finance and Economics from London School of Economics, Dual Bachelor in Advertising and Economics from Peking University. Previously Director in Nextcore Asset Management Limited and Vendavel Asset Management Limited, Vice President in China Orient International Asset Management Limited Hong Kong, Senior Investment Manager in Credit Ease Wealth Management (HK) Limited.

    Chief Operating Officer HBM Partners Hong Kong Limited
    Read more
  • Nina Good

    Nina Good

    Over twenty years of experience in the financial industry including both Investment Banking as well as Private Wealth Management for UBS. Several years experience covering Compliance for Schroder Investment Management (Switzerland), a fund management company, asset manager and Swiss representative of foreign funds. Holds a Bachelor of Science ZFH in Business Administration from HWZ (University of Applied Sciences in Business Administration Zurich), a DAS in Compliance Management from Hochschule Luzern/FHZ (Lucerne University of Applied Sciences) as well as a CFA Claritas Diploma.   

    Head Compliance
    Read more
  • Thomas Heimann

    Thomas Heimann

    Over 8 years experience in Investment Research, Analysis, FINMA Risk Mgmt. and client services. Master and Bachelor of Science in Banking & Finance from the Lucerne University of Applied Sciences and Arts. Previously worked in investment analysis and valuation and in client advisory at a Swiss bank.

    Head Operations & Investment Solutions
    Read more
  • Ny Ken

    Ny Ken

    More than 10 years experience in trading & execution and administration. Bachelor in business administration from Zurich University of Applied Sciences. Previously in administrative functions at HBM Partners AG.
     

    Investment Control Public Equity
    Read more
  • Dominique Küttel

    Dominique Küttel

    Over fifteen years of experience in banking and asset management at UBS and Gottex Fund Management in Switzerland and in England . His activities included product structuring, offering tailor-made solutions in the alternative area, leading European sales as well as managing several sales and product teams. He has two Masters and a Doctorate in Economics with specialization in econometrics and financial markets at the universities of Basel, Lausanne ( HEC ), Geneva ( HEI ) and the Study Center Gerzensee. 

    Head Business Development & Distribution
    Dr.
    Read more
  • Miles Schofield

    Miles Schofield

    Over 15 years experience in trading & execution. Bachelors of Science (Hons) degree from the Open University.
    Previously in US Equities Middle Office activities at Salomon Smith Barney and Citigroup.
     

    Trading & Execution Public Equity
    Read more
  • Raphael Weibel

    Raphael Weibel

    Over 6 years experience in the financial industry, gained in auditing at KPMG and banking at Reichmuth & Co. Privatbank. Holds a Bachelor in Business and Economics and a Bachelor in Geography from Zurich University of Applied Sciences. Has previously worked in medical regulatory affairs. 

    Head Risk Management
    Read more
  • Claudia Capucho

    Claudia Capucho

     

    Office Manager
  • Sanna Hobbs

    Sanna Hobbs

     

    Assistant Public Equity
  • Karin Rickenbacher

     Karin Rickenbacher

     

    Accounting
  • Jennifer Toumi

    Jennifer Toumi

     

    Assistant Private Equity
  • Sonja Zwyer

    Sonja Zwyer

     

    Reception

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171